Overcoming the clinical challenges of traditional ayahuasca: a first-in-human trial exploring novel routes of administration of N,N-Dimethyltryptamine and harmine.
Saved in:
| Title: | Overcoming the clinical challenges of traditional ayahuasca: a first-in-human trial exploring novel routes of administration of N,N-Dimethyltryptamine and harmine. |
|---|---|
| Authors: | Dornbierer DA; Institute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland.; Department of Forensic Pharmacology and Toxicology, Zurich Institute of Forensic Medicine, University of Zurich, Zurich, Switzerland.; Department of Psychiatry, Psychotherapy and Psychosomatics, University Hospital of Psychiatry Zurich, Zurich, Switzerland., Marten L; Department of Psychiatry, Psychotherapy and Psychosomatics, University Hospital of Psychiatry Zurich, Zurich, Switzerland.; Department of Chemistry and Applied Biosciences, Zurich, Switzerland., Mueller J; Department of Psychiatry, Psychotherapy and Psychosomatics, University Hospital of Psychiatry Zurich, Zurich, Switzerland., Aicher HD; Department of Psychiatry, Psychotherapy and Psychosomatics, University Hospital of Psychiatry Zurich, Zurich, Switzerland.; Department of Psychology, University of Zurich, Zurich, Switzerland.; Neuroscience Center Zurich, University of Zurich and ETH Zurich, Zurich, Switzerland., Mueller MJ; Department of Psychiatry, Psychotherapy and Psychosomatics, University Hospital of Psychiatry Zurich, Zurich, Switzerland.; Neuroscience Center Zurich, University of Zurich and ETH Zurich, Zurich, Switzerland.; Department of Health Science & Technology, Zurich, Switzerland., Boxler M; Department of Forensic Pharmacology and Toxicology, Zurich Institute of Forensic Medicine, University of Zurich, Zurich, Switzerland., Kometer M; Reconnect Labs, Winterthur, Switzerland., Kosanic D; Reconnect Labs, Winterthur, Switzerland., von Rotz R; Department of Psychiatry, Psychotherapy and Psychosomatics, University Hospital of Psychiatry Zurich, Zurich, Switzerland., Puchkov M; Institute of Pharmaceutical Technology, University of Basel, Basel, Switzerland., Kraemer T; Department of Forensic Pharmacology and Toxicology, Zurich Institute of Forensic Medicine, University of Zurich, Zurich, Switzerland., Landolt HP; Institute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland.; Neuroscience Center Zurich, University of Zurich and ETH Zurich, Zurich, Switzerland., Seifritz E; Department of Psychiatry, Psychotherapy and Psychosomatics, University Hospital of Psychiatry Zurich, Zurich, Switzerland.; Neuroscience Center Zurich, University of Zurich and ETH Zurich, Zurich, Switzerland., Scheidegger M; Department of Psychiatry, Psychotherapy and Psychosomatics, University Hospital of Psychiatry Zurich, Zurich, Switzerland.; Neuroscience Center Zurich, University of Zurich and ETH Zurich, Zurich, Switzerland. |
| Source: | Frontiers in pharmacology [Front Pharmacol] 2023 Nov 27; Vol. 14, pp. 1246892. Date of Electronic Publication: 2023 Nov 27 (Print Publication: 2023). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Media] Country of Publication: Switzerland NLM ID: 101548923 Publication Model: eCollection Cited Medium: Print ISSN: 1663-9812 (Print) Linking ISSN: 16639812 NLM ISO Abbreviation: Front Pharmacol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 38089057 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Overcoming the clinical challenges of traditional ayahuasca: a first-in-human trial exploring novel routes of administration of N,N-Dimethyltryptamine and harmine. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Dornbierer+DA%22">Dornbierer DA</searchLink>; Institute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland.; Department of Forensic Pharmacology and Toxicology, Zurich Institute of Forensic Medicine, University of Zurich, Zurich, Switzerland.; Department of Psychiatry, Psychotherapy and Psychosomatics, University Hospital of Psychiatry Zurich, Zurich, Switzerland.<br /><searchLink fieldCode="AU" term="%22Marten+L%22">Marten L</searchLink>; Department of Psychiatry, Psychotherapy and Psychosomatics, University Hospital of Psychiatry Zurich, Zurich, Switzerland.; Department of Chemistry and Applied Biosciences, Zurich, Switzerland.<br /><searchLink fieldCode="AU" term="%22Mueller+J%22">Mueller J</searchLink>; Department of Psychiatry, Psychotherapy and Psychosomatics, University Hospital of Psychiatry Zurich, Zurich, Switzerland.<br /><searchLink fieldCode="AU" term="%22Aicher+HD%22">Aicher HD</searchLink>; Department of Psychiatry, Psychotherapy and Psychosomatics, University Hospital of Psychiatry Zurich, Zurich, Switzerland.; Department of Psychology, University of Zurich, Zurich, Switzerland.; Neuroscience Center Zurich, University of Zurich and ETH Zurich, Zurich, Switzerland.<br /><searchLink fieldCode="AU" term="%22Mueller+MJ%22">Mueller MJ</searchLink>; Department of Psychiatry, Psychotherapy and Psychosomatics, University Hospital of Psychiatry Zurich, Zurich, Switzerland.; Neuroscience Center Zurich, University of Zurich and ETH Zurich, Zurich, Switzerland.; Department of Health Science & Technology, Zurich, Switzerland.<br /><searchLink fieldCode="AU" term="%22Boxler+M%22">Boxler M</searchLink>; Department of Forensic Pharmacology and Toxicology, Zurich Institute of Forensic Medicine, University of Zurich, Zurich, Switzerland.<br /><searchLink fieldCode="AU" term="%22Kometer+M%22">Kometer M</searchLink>; Reconnect Labs, Winterthur, Switzerland.<br /><searchLink fieldCode="AU" term="%22Kosanic+D%22">Kosanic D</searchLink>; Reconnect Labs, Winterthur, Switzerland.<br /><searchLink fieldCode="AU" term="%22von+Rotz+R%22">von Rotz R</searchLink>; Department of Psychiatry, Psychotherapy and Psychosomatics, University Hospital of Psychiatry Zurich, Zurich, Switzerland.<br /><searchLink fieldCode="AU" term="%22Puchkov+M%22">Puchkov M</searchLink>; Institute of Pharmaceutical Technology, University of Basel, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Kraemer+T%22">Kraemer T</searchLink>; Department of Forensic Pharmacology and Toxicology, Zurich Institute of Forensic Medicine, University of Zurich, Zurich, Switzerland.<br /><searchLink fieldCode="AU" term="%22Landolt+HP%22">Landolt HP</searchLink>; Institute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland.; Neuroscience Center Zurich, University of Zurich and ETH Zurich, Zurich, Switzerland.<br /><searchLink fieldCode="AU" term="%22Seifritz+E%22">Seifritz E</searchLink>; Department of Psychiatry, Psychotherapy and Psychosomatics, University Hospital of Psychiatry Zurich, Zurich, Switzerland.; Neuroscience Center Zurich, University of Zurich and ETH Zurich, Zurich, Switzerland.<br /><searchLink fieldCode="AU" term="%22Scheidegger+M%22">Scheidegger M</searchLink>; Department of Psychiatry, Psychotherapy and Psychosomatics, University Hospital of Psychiatry Zurich, Zurich, Switzerland.; Neuroscience Center Zurich, University of Zurich and ETH Zurich, Zurich, Switzerland. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101548923%22">Frontiers in pharmacology</searchLink> [Front Pharmacol] 2023 Nov 27; Vol. 14, pp. 1246892. <i>Date of Electronic Publication: </i>2023 Nov 27 (<i>Print Publication: </i>2023). – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Media]%22">Frontiers Media] </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101548923 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>1663-9812 (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2216639812%22">16639812 </searchLink><i>NLM ISO Abbreviation: </i>Front Pharmacol <i>Subsets: </i>PubMed not MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38089057 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.3389/fphar.2023.1246892 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 1246892 Titles: – TitleFull: Overcoming the clinical challenges of traditional ayahuasca: a first-in-human trial exploring novel routes of administration of N,N-Dimethyltryptamine and harmine. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Dornbierer DA – PersonEntity: Name: NameFull: Marten L – PersonEntity: Name: NameFull: Mueller J – PersonEntity: Name: NameFull: Aicher HD – PersonEntity: Name: NameFull: Mueller MJ – PersonEntity: Name: NameFull: Boxler M – PersonEntity: Name: NameFull: Kometer M – PersonEntity: Name: NameFull: Kosanic D – PersonEntity: Name: NameFull: von Rotz R – PersonEntity: Name: NameFull: Puchkov M – PersonEntity: Name: NameFull: Kraemer T – PersonEntity: Name: NameFull: Landolt HP – PersonEntity: Name: NameFull: Seifritz E – PersonEntity: Name: NameFull: Scheidegger M IsPartOfRelationships: – BibEntity: Dates: – D: 27 M: 11 Text: 2023 Nov 27 Type: published Y: 2023 Identifiers: – Type: issn-print Value: 1663-9812 Numbering: – Type: volume Value: 14 Titles: – TitleFull: Frontiers in pharmacology Type: main |
| ResultId | 1 |